Antiepileptic drugs in pediatric epilepsy

Journal of Pediatric Neurosciences

Volumn 3, Issue 1 SUPPL., 2008, Pages 7-15

  Ravat, Sangeeta ^a   Gupta, Rohit ^a  

^a KEM HOSPITAL   (India)

Author keywords

Antiepileptic drugs; Epilepsy; Seizure

Indexed keywords

ACETAZOLAMIDE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; CORTICOSTEROID; CORTICOTROPIN; DIAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; LAMOTRIGINE; NITRAZEPAM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; PYRIDOXINE; STIRIPENTOL; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ABDOMINAL PAIN; AGITATION; ALLERGIC RASH; ANOREXIA; APLASTIC ANEMIA; APPETITE DISORDER; ASTHENIA; ATAXIA; AUDITORY HALLUCINATION; BLOOD DYSCRASIA; CLINICAL PRACTICE; COARSE FACE; COGNITIVE DEFECT; CONFUSION; CONGESTIVE HEART FAILURE; COORDINATION DISORDER; CUSHINGOID SYNDROME; DEPRESSION; DIARRHEA; DIPLOPIA; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG HALF LIFE; DYSPEPSIA; ELECTROENCEPHALOGRAPHY; EPIGASTRIC PAIN; EPILEPSY; FATIGUE; FOCAL EPILEPSY; GASTROINTESTINAL SYMPTOM; GENERALIZED EPILEPSY; GINGIVA HYPERPLASIA; GLAUCOMA; HAIR LOSS; HEADACHE; HIRSUTISM; HUMAN; HYPERAMMONEMIA; HYPERGLYCEMIA; HYPERPHOSPHATEMIA; HYPERTENSION; HYPNOSIS; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; INFECTION; INSOMNIA; IRRITABILITY; JAUNDICE; KIDNEY FAILURE; LANGUAGE DISABILITY; LEUKOPENIA; LIVER DYSFUNCTION; LIVER FAILURE; LIVER TOXICITY; MENTAL CONCENTRATION; METABOLIC ACIDOSIS; MONOTHERAPY; MUSCLE CRAMP; MUSCLE FATIGUE; MYOCLONUS SEIZURE; NAUSEA; NAUSEA AND VOMITING; NEPHROLITHIASIS; NEUROIMAGING; NEUROSURGERY; NOCTURNAL ENURESIS; NYSTAGMUS; PARESTHESIA; PEDIATRICS; PERIPHERAL EDEMA; POLYPHARMACY; PRACTICE GUIDELINE; PSYCHOMOTOR DISORDER; PSYCHOSIS; RASH; REVIEW; SEDATION; SIDE EFFECT; SKIN TINGLING; SOMNOLENCE; TASTE DISORDER; THROMBOCYTOPENIA; TONIC CLONIC SEIZURE; TREMOR; VISUAL HALLUCINATION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; WEST SYNDROME;

EID: 43449085228     PISSN: 18171745     EISSN: 19983948     Source Type: Journal    
DOI: 10.4103/1817-1745.40585     Document Type: Review

References (67)

1. Zupanc ML. Update on epilepsy in pediatric patients. Mayo Clin Proc 1996;71:899-916.
2. Pellock JM, Watemberg N. New antiepileptic drugs in children: Present and future. Sem Pediatr Neurol 1997;4:9-18.
3. Aicardi J, Arzimanoglou A. Treatment of childhood epilepsy syndromes. In: Shorvon SD, Dreifuss FE, Fish D, Thomas D, editors. The treatment of epilepsy. Blackwell Science: London; 1996. p. 199-214.
4. Aldenkamp AP. Effects of antiepileptic drugs on cognition. Epilepsia 2001;42:46-9.
5. rd ed. Lippincott Williams and Wilkins: Phildelphia; 2001. p. 1215-25.
6. de Silva M, McArdle B, McGowan M. Monotherapy for newly diagnosed childhood epilepsy: A comparative trial and prognostic evaluation. Epilepsia 1989;30:662A.
7. rd, Hosey LC. Exacerbation of seizures in children by carbamazepine. N Engl J Med 1985;313:916-21.
8. Isojärvi JI, Huuskonen UE, Pakarinen AJ, Vuolteenaho O, Myllylä VV. The regulation of serum sodium after replacing carbamazepine with oxcarbamazepine. Epilepsia 2001;42:741-5.
9. Seigler RS, The administration of rectal diazepam for acute management of seizures. J Emerg Med 1990;8:155-9.
10. Kriel RL, Cloyd JC, Pellock JM, Mitchell WG, Cereghino JJ, Rosman NP. Rectal diazepam gel for treatment of acute repetitive seizures. Pediatr Neurol 1999;20:282-8.
11. Mitchell WG, Conry JA, Crumrine PK, Kriel RL, Cereghino JJ, Groves L, et al. An open-label study of repeated use of rectal diazepam gel (Diastat) for episodes of acute breakthrough seizures and clusters: Safety, efficacy and tolerance. Epilepsia 1999;40:1610-7.
12. Albano A, Reisdorff EJ, Wiegenstein JG. Rectal diazepam in pediatric status epilepticus. Am J Emerg Med 1989;7:168-72.
13. Camfield CS, Camfield PR, Smith E, Dooley JM. Home use of rectal diazepam to prevent status epilepticus in children with convulsive disorders. J Child Neurol 1989;4:125-6.
14. Devinsky O, Kothari M, Rubin R. Felbamate for absence seizures. Epilepsia 1992;33:84.
15. Hurst DL, Rolan TD. The use of felbamate to treat infantile spasms. J Child Neurol 1995;10:134-6.
16. Stafstrom CE. The use of felbamate to treat infantile spasms. J Child Neurol 1996;11:170-1.
17. Hosain S, Nagarajan L, Carson D, Solomon G, Mast J, Labar D. Felbamate for refractory infantile spasms. J Child Neurol 1997;12:466-8.
18. Glauser TA, Olberding LS, Titanic MK, Piccirillo DM. Felbamate in the treatment acquired epileptic aphasia. Epilepsy Res 1995;20:85-9.
19. Painter MJ, Pippinger C, Wasterlain C, Barmada M, Pitlick W, Carter G, et al. Phenobarbital and phenytoin in neonatal seizures: metabolism and tissue distribution. Neurology 1981;31:1107-12.
20. Painter MJ, Scher MS, Stein AD, Armatti S, Wang Z, Gardiner JC, et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. N Engl J Med 1999;341:485-9.
21. Bourgeois BF, Holder DL, Valencia I. Open-label assessment of levetiracetam efficacy and adverse effects in a pediatric population. Epilepsia 2001;42:53-4.
22. Gustafson MC, Ritter FJ, Karney VL, Hoskin C. Clinical experience with levetiracetam treating refractory, symptomatic seizures in children. Epilepsia 2001;42:55.
23. Kossof EH, Bergey GK, Freeman JM, Vining EP. Levetiracetam psychosis in children with epilepsy. Epilepsia 2001;42:1611-3.
24. Powell C, Painter MJ, Pippinger CE. Primidone therapy in refractory neonatal seizures. J Pediatr 1984;105:651-4.
25. Sapin JI, Riviello JJ Jr, Grover WD. Efficacy of primidone for seizure control in neonates and young infants. Pediatr Neurol 1988;4:292-5.
26. Schapel G, Chadwick D. Tiagabine and non-convulsive status epilepticus. Seizure 1996;5:153-6.
27. Ettinger AB, Bernal OG, Andriola MR, Bagchi S, Flores P, Just C, et al. Two cases on non-convulsive status epilepticus in association with tiagabine therapy. Epilepsia 1999;40:1159-62.
28. rd, Liporace J, Kanner A, et al. Poatmarketing experience with Topiramate and cognition. Epilepsia 2001;42:1134-40.
29. Martin R, Kuzniecky R, Ho S, Hetherington H, Pan J, Sinclair K, et al. Cognitive effects of Topiramate, gabapentine and lamotrigine in healthy young adults. Neurology 1999;52:321-7.
30. Shorvon SD. Safety of Topiramate: Adverse events and relationships to dosing. Epilepsia 1996;37:S18-22.
31. Wilner A, Raymond K, Pollard R. Topiramate and metabolic acidosis. Epilepsia 1999;40:792-5.
32. Takeoka M, Holmes GL, Thiele E, Bourgeois BF, Helmers SL, Duffy FH, et al. Topiramate and metabolic acidosis in pediatric epilepsy. Epilepsia 2001;42:387-92.
33. Rantala H, Tarkka R, Uhari M. A meta-analysis review of the preventive treatment of recurrences of febrile seizures. J Pediatr 1997;131:922-5.
34. rd, Dreifuss FE. Valproic acid hepatic fatalities: III, US experience since 1986. Neurology 1996;46:465-9.
35. Choonra IA. Sodium Valproate and enuresis. Lancet 1985;1:1276.
36. Lindhout D, Meinardi H. Spina bifida and in utero exposure to Valproate. Lancet 1984;2:396.
37. Omtzigt JG, Los FJ, Grobbee DE, Pijpers L, Jahoda MG, Brandenburg H, et al. The risk of spina bifida aperta after first trimester exposure to valproate in a prenatal cohort. Neurology 1992;42:119-25.
38. Chiron C, Dulac O, Beaumont D, Palacios L, Pajot N, Mumford J. Therapeutic trial of vigabatrin in infantile spasms. J Child Neurol 1991;2:S52-9.
39. Aicardi J, Mumford J, Dumas C, Wood S. Vigabatrin as initial therapy for infantile spasms: European retrospective survey. Epilepsia 1996;37:638-42.
40. Vigevano F, Cilino M. Vigabatrin versus ACTH as first-line treatment for infantile spasms: A randomized, prospective study. Epilepsia 1997;38:1270-4.
41. Appleton RE, Peters AC, Mumford JP, Shaw DE. Randomised, placebo-controlled study of Vigabatrin as first-line treatments of infantile spasms. Epilepsia 1999;40:1627-33.
42. Granström ML, Gaily E, Liukkonen E. Treatment of infantile spasms: Result of a population-based study with Vigabatrin as the first drug foe spasms. Epilepsia 1999;40:950-7.
43. Elterman RD, Shields WD, Mansfield KA, Nakagawa J; US Infantile Spasms Vigabatrin Study Group. Randomised trial of Vigabatrin in patients with infantile spasms. Neurology 2001;57:1416-21.
44. Miller NR, Johnson MA, Paul SR, Girkin CA, Perry JD, Endres M, et al. Visual dysfunction in patients receiving vigabatrin: Clinical and electrophysiologic findings. Neurology 1999;53:2082-7.
45. Vanhatalo S, Paakkonen L. Visual field constriction in children treated with Vigabatrin. Neurology 1999;1:1713-4.
46. Gross-Tsur V, Banin E, Shahar E, Shalev RS, Lahat E. Visual impairement in children with epilepsy treated with Vigabatrin. Ann Neurol 2000;48:60-4.
47. Lortie A, Chiron C, Mumford J, Dulac O. The potential for increasing seizure frequency, repase and appearance of new seizures types with Vigabatrin. Neurology 1993;43:S24-7.
48. Panayiotopoulus CP, Agathonikou A, Ahmed Sharoqi I, Parker AP. Vigabatrin aggravates absences and absence status. Neurology 1997;49:1467.
49. Kuenzle C, Steinlin J, Wahlrab G, Boltshauser E, Schmitt B. Adverse effects of Vigabatrin in Angelman syndrome. Epilepsia 1998;39:1213-5.
50. Kumagai N, Seki T, Yamawaki H, Suzuki N, Kimiya S, Yamada T, et al. Monotherapy for childhood epilepsies with zoniszmide. Jpn J Psychiatry Neurol 1991;45:357-9.
51. Suzuki Y, Nagai T, Ono J, Imai K, Otani K, Tagawa T, et al. Zonisamide monotherapy in newly diagnosed infantile spasms. Epilepsia 1997;38:1035-8.
52. Yanai S, Hanai T, Narazaki O. Treatment of infantile spasms with zonisamide. Brain Dev 1999;21:157-61.
53. Ohno M, Shimotsuji Y, Abe J, Shimada M, Tamiya H. Zonisamide treatment of early infantile epileptic encephalopathy. Pediatr Neurol 2000;23:341-4.
54. Henry TR, Leppik IE, Gumnit RJ, Jacobs M. Progressive myoclonus epilepsy treated with zonisamide. Neurology 1988;38:928-31.
55. Kyllerman M, Ben-Menachem E. Long-term treatment of progressive myoclonic epilepsy syndromes with zonisamide and n-acetylcysteine. Epilepsia 1996;37:172.
56. Yoshimura I, Kaneko S, Yoshimura N, Murakami T. Long-term observations of two siblings with Lafora disease treated with zonisamide. Epilepsy Res 2001;46:283-7.
57. Miyamoto T, Kohsaka M, Koyama T. Psychotic episodes during zonisamide treatment. Seizure 2000;9:65-70
58. Leppik IE. Zonisamide. Epilepsia 1999;40:23-9.
59. Kubota M, Nishi-Nagase M, Sakakihara Y, Noma S, Nakamoto M, Kawaguchi H, et al. Zonisamide-induced urinary lithiasis in patients with intractable epilepsy. Brain Dev 2000;22:230-3.
60. Shimizu T, Yamashita Y, Satoi M, Togo A, Wada N, Matsuishi T, et al. Heat stroke-like episode in a child caused by zonisamide. Brain Dev 1997;19:366-8.
61. Okumura A, Ishihara N, Kato T, Hayakawa F, Kuno K, Watanabe K. Predictive value of acetylcholine stimulation testing for oligohidrosis caused by zonisamide. Pediatr Neurol 2000;23:59-61.
62. rd ed. Lippincott Williams and Wilkins: Philadelphia; 2001. p. 969-75.
63. Mikati MA, Trevathan E, Krishnamoorthy KS, Lombroso CT. Pyridoxine dependent epilepsy: EEG investigations and long-term follow up. Electroencephalogr Clin Neurophysiol 1991;78:215-21.
64. Pietz J, Benninger C, Schäfer H, Sontheimer D, Mittermaier G, Rating D. Treatment of infantile spasms with high-dose vitamin B6. Epilepsia 1993;34:757-63.
65. Brodie MJ, Mumford JP. Double-blind substitution of Vigabatrin and Valproate in carbamazepine-resistant partial epilepsy. Epilepsy Res 1999;34:199-205.
66. Reynolds EH, Shorvon SD. Monotherapy or polytherapy for epilepsy. Epilepsia 1981;22:1-10.
67. Matricardi M, Brinciotti M, Benedetti P. Outcome after discontinuation of AED therapy in children with epilepsy. Epilepsia 1989;30:582-9.